These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 3733227

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cefpirome susceptibility in staphylococci isolates.
    Poiată A, Tuchiluş C, Bădicuţ I, Buiuc D.
    Rev Med Chir Soc Med Nat Iasi; 2007; 111(1):276-9. PubMed ID: 17595881
    [Abstract] [Full Text] [Related]

  • 3. Comparative in vitro activity of cefpirome and other antimicrobial agents against isolates from cancer patients.
    Rolston K, Alvarez ME, Hoy JF, LeBlanc B, Ho DH, Bodey GP.
    Chemotherapy; 1986; 32(4):344-51. PubMed ID: 3731920
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Activity of cefpirome against bacteria isolated from hospitalized patients].
    Fernández A, Herran I, de Mier C, Marcenac FM.
    Medicina (B Aires); 1989; 49(4):373-8. PubMed ID: 2487748
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of SCH-34343, a new penam, and other antimicrobial agents against clinical isolates from cancer patients.
    Rolston KV, Alvarez ME, Hoy JF, Alderman HC, Ho DH, Bodey GP.
    Chemotherapy; 1986; 32(6):506-14. PubMed ID: 3100147
    [Abstract] [Full Text] [Related]

  • 9. In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
    Rolston KV, Alvarez ME, Hoy JF, Alderman HC, Ho DH, Bodey GP.
    J Antimicrob Chemother; 1986 Aug; 18(2):159-62. PubMed ID: 3093447
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of cefpirome against microorganisms isolated in haematology, oncology and intensive care units in Switzerland.
    Liassine N, Bille J, Breer C, Frei R, Wüst J, Auckenthaler R.
    Scand J Infect Dis; 1997 Aug; 29(6):615-21. PubMed ID: 9571744
    [Abstract] [Full Text] [Related]

  • 11. Comparative antibacterial activity of the new oral cephalosporin BMY-28100.
    Kayser FH.
    Eur J Clin Microbiol; 1987 Jun; 6(3):309-12. PubMed ID: 3497804
    [Abstract] [Full Text] [Related]

  • 12. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
    Chamberland S, Blais J, Hoang M, Dinh C, Cotter D, Bond E, Gannon C, Park C, Malouin F, Dudley MN.
    Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of clarithromycin, cefprozil, and other common oral antimicrobial agents against gram-positive and gram-negative pathogens.
    Ritchie DJ, Hopefl AW, Milligan TW, Byrne JE, Maddux MS.
    Clin Ther; 1993 May; 15(1):107-13. PubMed ID: 8458040
    [Abstract] [Full Text] [Related]

  • 14. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 15. Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime.
    Bauernfeind A.
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():155-64. PubMed ID: 3897170
    [Abstract] [Full Text] [Related]

  • 16. In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
    Inoue K, Inoue E, Mitsuhashi S.
    Chemotherapy; 1995 Jun; 41(4):257-66. PubMed ID: 7555206
    [Abstract] [Full Text] [Related]

  • 17. In-vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative staphylococci.
    Raymond J, Vedel G, Bergeret M.
    J Antimicrob Chemother; 1996 Dec; 38(6):1067-71. PubMed ID: 9023655
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide-intermediate Staphylococcus aureus.
    Swenson JM, Tenover FC.
    J Antimicrob Chemother; 2002 May; 49(5):845-50. PubMed ID: 12003982
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM, Aranza MK, Shah D, Sahm DF.
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.